Follow us on Twitter
twitter icon@FreshPatents


Arteriosclerosis patents

      

This page is updated frequently with new Arteriosclerosis-related patent applications.




 Composition for treating or preventing metabolic disease, containing, as active ingredient, extracellular vesicles derived from akkermansia muciniphila bacteria patent thumbnailComposition for treating or preventing metabolic disease, containing, as active ingredient, extracellular vesicles derived from akkermansia muciniphila bacteria
The present invention relates to a pharmaceutical and food composition for treating, preventing, or alleviating a metabolic disease, containing, as an active ingredient, extracellular vesicles derived from akkermansia muciniphila. The composition of the present invention can be used as a pharmaceutical/food composition and the like for treating, preventing, or alleviating metabolic diseases, in particular metabolic diseases such as obesity, diabetes, hyperlipidemia, arteriosclerosis, and hypertension, occurring or exacerbated due to a high fat diet.
Md Healthcare Inc.


 Variants of c-type natriuretic peptide patent thumbnailVariants of c-type natriuretic peptide
The present disclosure provides variants of c-type natriuretic peptide (cnp), pharmaceutical compositions comprising cnp variants, and methods of making cnp variants. The cnp variants are useful as therapeutic agents for the treatment of diseases responsive to cnp, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis)..
Biomarin Pharmaceutical Inc.


 Pentylenetetrazole derivatives patent thumbnailPentylenetetrazole derivatives
Wherein r1, r2, r3, r4, r5, r6, r7, r8, r9, and r10 are as disclosed herein, or a pharmaceutically salt thereof. Pharmaceutical compositions comprising the compounds and methods of their use, for instance in treating senility, senile confusion, psychoses, psychoneuroses when anxiety and nervous tension were present, cerebral arteriosclerosis, nausea, depression, fatigue, debilitation, mild behavioral disorders, irritability, emotional instability, antisocial attitudes, anxiety, vertigo or incontinence, or symptom thereof, or in improving cognitive function in individuals, for instance, in individuals with down syndrome and other conditions, are also provided..

 Agent for preventing or ameliorating vascular endothelial malfunction patent thumbnailAgent for preventing or ameliorating vascular endothelial malfunction
An agent for preventing or ameliorating vascular endothelial malfunction and arteriosclerosis-related symptoms caused by the progress of vascular endothelial malfunction (e.g., ischemic diseases such as myocardial infarction, angina, and peripheral artery occlusion) or low blood flow-related symptoms (e.g., stiff shoulders, excessive sensitivity to cold, swelling, erectile dysfunction, rough skin and decrease in exercise performance due to skeletal muscle hypoactivity), which has an improved no production enhancing effect is provided. A no production enhancer comprising citrulline or a salt thereof and glutathione or a salt thereof as active ingredients.
Kyowa Hakko Bio Co., Ltd.


 5-hydroxy-4-(trifluoromethyl)pyrazolopyridine derivative patent thumbnail5-hydroxy-4-(trifluoromethyl)pyrazolopyridine derivative
A compound represented by the general formula (i) or a pharmacologically acceptable salt thereof has an excellent lcat-activating effect and is useful as an active ingredient in a therapeutic or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disturbance, and restenosis caused by angiogenesis), cerebrovascular disease (including stroke and cerebral infarction), peripheral vascular disease (including diabetic vascular complications), dyslipidemia, hypo-hdl-cholesterolemia, hyper-ldl-cholesterolemia, or renal disease, particularly, an anti-arteriosclerotic agent, wherein r is an optionally substituted aryl group or an optionally substituted heteroaryl group, and r1 is a hydrogen atom or a hydroxy group.. .
Daiichi Sankyo Company, Limited


 Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders patent thumbnailMethods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders..
The Johns Hopkins University


 Dna vaccine containing specific epitope of apolipoprotein (a) patent thumbnailDna vaccine containing specific epitope of apolipoprotein (a)
The present invention provides an agent for the treatment or prophylaxis of arteriosclerosis comprising an expression vector encoding a chimeric hepatitis b virus core antigen polypeptide inserted with an amino acid sequence containing a specific epitope of apolipoprotein (a), wherein the amino acid sequence containing the specific epitope is inserted between the amino acid residues 80 and 81 of the hepatitis b virus core antigen polypeptide.. .
Angesmg, Inc.


 Agent for preventing or ameliorating vascular endothelial malfunction patent thumbnailAgent for preventing or ameliorating vascular endothelial malfunction
An agent for preventing or ameliorating vascular endothelial malfunction and arteriosclerosis-related symptoms caused by the progress of vascular endothelial malfunction (e.g., ischemic diseases such as myocardial infarction, angina, and peripheral artery occlusion) or low blood flow-related symptoms (e.g., stiff shoulders, excessive sensitivity to cold, swelling, erectile dysfunction, rough skin and decrease in exercise performance due to skeletal muscle hypoactivity), which has an improved no production enhancing effect is provided. A no production enhancer comprising citrulline or a salt thereof and glutathione or a salt thereof as active ingredients.
Kyowa Hakko Bio Co., Ltd.


 Continuous arycyclic compound patent thumbnailContinuous arycyclic compound
This is to provide a continuous arycyclic compound having a dgat1 inhibitory activity, and useful for prophylaxis and/or treatment of obesity or hyperlipidemia caused by obesity, hypertriglyceridemia, lipid metabolism disorder, fatty liver, hypertension, arteriosclerosis, diabetes, etc., as well as to provide a dgat1 inhibitor comprising the continuous arycyclic compound or a pharmaceutically acceptable salt thereof as an effective ingredient. Disclosed is the continuous arycyclic compound is represented by the formula: wherein the substituents in the formula are the same as defined in the specification, or a pharmaceutically acceptable salt thereof..
Mitsubishi Tanabe Pharma Corporation


 Variants of c-type natriuretic peptide patent thumbnailVariants of c-type natriuretic peptide
The present disclosure provides variants of c-type natriuretic peptide (cnp), pharmaceutical compositions comprising cnp variants, and methods of making cnp variants. The cnp variants are useful as therapeutic agents for the treatment of diseases responsive to cnp, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis)..
Biomarin Pharmaceutical Inc.


Compositions for treating or preventing cardiovascular disease

Vitamin k is effective in counteracting cardiovascular disorders such as the reduction in arterial elasticity normally associated with the aging process. A pharmaceutical composition or nutritional formulation comprising vitamin k can be used to combat age-related stiffening of the arteries, and the consequences thereof, namely pulmonary congestion, hypertension, left ventricular hypertrophy, congestive (right sided) heart failure, left sided or left ventricular failure, chronic cardiac failure, angina pectoris, myocardial infarction, mönckeberg's sclerosis and stroke.
Nattopharma Asa

Cardiovascular disease treatment and prevention

The present invention generally relates to compositions and methods for treatment of subjects having or at risk of arteriosclerosis, hypertension, sickle-cell anemia, or other conditions. In some cases, the composition may include nitric oxide, peptides, or both.
Transdermal Biotechnology, Inc.

Composition for treating hyperlipidemia comprising oxyntomodulin derivative

The present invention relates to a composition for preventing or treating hyperlipidemia, fatty liver disease or arteriosclerosis, comprising an oxyntomodulin derivative as an active ingredient. The oxyntomodulin derivative has a high ability to activate glp-1 receptor and glucagon receptor compared to native oxyntomodulin and has the effects of reducing the blood total cholesterol, low-density cholesterol and triglyceride levels that were increased by high-fat diet, and increasing high-density cholesterol levels and the high-density cholesterol/low-density cholesterol ratio.
Hanmi Pharm. Co., Ltd.

Cardiovascular disease treatment and prevention

The present invention generally relates to compositions and methods for treatment of subjects having or at risk of arteriosclerosis, hypertension, sickle-cell anemia, or other conditions. In some cases, the composition may include nitric oxide, peptides, or both.
Transdermal Biotechnology, Inc.

Prevention and treatment of cardiovascular diseases using transdermal nitric oxide delivery

The present invention generally relates to compositions and methods for treatment of subjects having or at risk of arteriosclerosis, hypertension, sickle-cell anemia, or other conditions. In some cases, the composition may include nitric oxide.
Transdermal Biotechnology, Inc.

Method for increasing bio-derived low molecular weight compound

The present invention is aimed to scientifically examine a change of a living body by exposing the living body in an electric field generated by a high voltage (such an action will be hereinafter also referred to “electric field exposure”), elucidate a detailed mechanism of action of a therapeutic effect by a potential therapeutic device, and find out its new use applications. The present invention is to provide a method for increasing a bio-derived low molecular weight compound including exposing a living body in an electric field generated by impressing a high voltage between electrodes or between an electrode and a ground; and a method for treating/improving a disease or a symptom thereof, the method including exposing a patient of a disease selected from bulimia, metabolic syndrome, obesity, diabetes, hyperlipemia, arteriosclerosis, headache, lumbago, stomachache, neuralgia, dementia, and sarcopenia in an electric field generated by impressing a high voltage of 9,000 to 18,000 v between electrodes or between an electrode and a ground..
Hakuju Institute For Health Science Co., Ltd.

Method for risk stratification in stable coronary artery disease

An in vitro method for the risk stratification of patients with stable arteriosclerosis, especially stable coronary artery disease, is disclosed wherein the concentration of procalcitonin is determined in the circulation of such patients using a highly sensitive pct assay, and wherein within the range of pct concentrations in the typical normal range of healthy individuals cutoff values are defined which distinguish groups of individual patients with stable arteriosclerosis in accordance with personal cardiac risk, and patients are allotted to one of said risk groups on the basis of their individual pct concentrations.. .
B.r.a.h.m.s Gmbh

Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof

This invention provides compositions, methods and process of producing extracts from xanthoceras sorbifolia. The extract comprises alkaloids, coumarins, saccharides, proteins, polysaccharides, glycosides, saponins, tannins, acid, flavonoids and others.

Monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase

Provided is a monoclonal antibody or a fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.. .
Shionogi & Co., Ltd.

Lmna gene and its involvement in hutchinson-gilford progeria syndrome (hgps) and arteriosclerosis

Disclosed herein are point mutations in the lmna gene that cause hgps. These mutations activate a cryptic splice site within the lmna gene, which leads to deletion of part of exon 11 and generation of a mutant lamin a protein product that is 50 amino acids shorter than the normal protein.
Research Foundation For Mental Hygiene, Inc.

Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same

The present invention provides a dihydropyridazine-3,5-dione derivative or a salt thereof, or a solvate of the compound or the salt, a pharmaceutical drug, a pharmaceutical composition, a sodium-dependent phosphate transporter inhibitor, and a preventive and/or therapeutic agent for hyperphosphatemia, secondary hyperparathyroidism, chronic renal failure, chronic kidney disease, and arteriosclerosis associated with vascular calcification comprising the compound as an active ingredient, and a method for prevention and/or treatment.. .
Chugai Seiyaku Kabushiki Kaisha

Azole benzene derivative

The present invention provides: a compound represented by formula (i) or a pharmaceutically acceptable salt thereof, which has an excellent inhibitory activity on xanthine oxidase and is useful as a therapeutic agent or a prophylactic agent for diseases associated with xanthine oxidase, such as gout, hyperuricemia, tumor lysis syndrome, urinary tract stone, hypertension, dyslipidemia, diabetes, cardiovascular diseases including arteriosclerosis and heart failure, renal diseases including diabetic nephropathy, respiratory diseases including chronic obstructive pulmonary disease, inflammatory bowel disease or autoimmune diseases; and a medicine or a pharmaceutical composition comprising the compound or the salt as an active ingredient.. .
Teijin Pharma Limited

Mfap4 binding antibodies blocking the interaction between mfap4 and integrin receptors

Microfibrillar-associated protein 4 (mfap4) binding antibodies are provided to prevent or to inhibit the proliferation of vascular smooth muscle cells and neointima formation in blood vessels. Furthermore, there are provided antibodies that effectively inhibit remodelling of vessels and prevent progression of arteriosclerosis as well as restenosis of vessels.
Syddansk Universitet

Pharmaceutical or food composition comprising oldenlandia brachypoda, spergularia marina, disporum smilacinum, persicaria posumbu, or geum aleppicum

The present disclosure relates to a pharmaceutical composition or a food composition which has excellent activity of stimulating enteroendocrine cells while being safe with few side effects. The composition contains one or more of an oldenlandia brachypoda extract, a spergularia marina extract, a disporum smilacinum extract, a persicaria posumbu extract and a geum aleppicum extract as an active ingredient.
Korea Food Research Institute

Composition and food or drink

Compositions contain γ-oryzanol and biocompatible particles that incorporate γ-oryzanol inside thereof. The biocompatible particle may contain polylactideglycolide copolymer with a number mean particle size of 2.5 to 1,000 nm or a polyethylene glycol modification thereof.
Advanced Medical Frontier Co., Ltd.

Agent for preventing arteriosclerosis, agent for suppressing vascular intimal thickening and agent for improving vascular endothelial function

Provided is an agent having at least one of an improving effect on vascular endothelial functions and an inhibitory effect on vascular intimal thickening, as well as a prophylactic of arteriosclerosis, which have excellent safety, improve functions associated with the vascular endothelium, have effects of preventing various diseases associated with vascular endothelial functions and of inhibiting vascular intimal thickening, and may be expected to provide prophylactic effect on arteriosclerosis. The agents of the present invention contain, as an active component: (a) xaa-pro-pro, (b) a hydrolysate of animal milk casein containing xaa-pro-pro, or a concentrate thereof, or (c) a fermentation product containing ile-pro-pro and/or val-pro-pro obtained by fermenting a starting material containing milk protein with a bacterial strain of the species lactobacillus helveticus..
Calpis Co., Ltd

Blood flow promoting agent

The present invention provides a blood flow promoting agent containing citrulline or a salt thereof and capsaicin or capsaicinoids as active ingredients, which is safe even by long-term administration, a food with health claims and a functional food affording such action, particularly, a blood flow promoting agent exhibiting an effective vasodilatory action of capsaicin at a low dose free of irritant property, which can be applied to improvement of athletic performance exhibited in relation to peripheral vasodilatation, suppression of fat accumulation, improvement of skin quality, as well as securing blood circulation in ischemic disease and the like, relaxation of blood vessel biased to coarctation due to advancing age, lifestyle-related diseases and the like, prophylaxis of arteriosclerosis, and prophylaxis of stiff neck, feeling of cold, erectile dysfunction, thrombosis and the like due to blood flow disorder.. .
Kyowa Hakko Bio Co., Ltd.

Composition for inhibiting cellular senescence comprising quercetin-3-o-beta-d-glucuronide

The present invention relates to a composition for inhibiting cellular senescence comprising quercetin-3-o-β-d-glucuronide (q3ga) as an active ingredient, and provides a composition for inhibiting cellular senescence of fibroblasts or umbilical vein endothelial cells induced by adriamycin or replicative senescence of fibroblasts or umbilical vein endothelial cells. Specifically, the quercetin-3-o-β-d-glucuronide (q3ga) is characterized by being isolated from polygoni avicularis herba extract.

Pyridine derivative

Provided is a pyridine derivative represented by formula (i), a prodrug thereof, a pharmaceutically acceptable salt of the pyridine derivative or the prodrug, or a solvate of the pyridine derivative, the prodrug or the pharmaceutically acceptable salt, which is useful for treatment or prophylaxis of diseases associated with urat1 such as gout, hyperuricemia, hypertension, kidney diseases such as interstitial nephritis, diabetes, arteriosclerosis and lesch-nyhan syndrome.. .

Form-iii crystal of 2--n-(methylsulfonyl)acetamide, producing the same, and use thereof

Form-iii crystal of 2-{4-[n-(5,6-diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n-(methylsulfonyl)acetamide and a method of producing the crystal are provided. The form-iii crystal exhibits diffraction peaks in its x-ray powder diffraction spectrum at least at the following angles of diffraction 2θ when the spectrum is obtained by using cu kα radiation: 9.3 degrees, 9.7 degrees, 16.8 degrees, 20.6 degrees, and 23.5 degrees.
Nippon Shinyaku Co., Ltd.

Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis

The present invention provides materials and methods for antagonizing the function of vascular endothelial growth factor receptors, platelet derived growth factor receptors and other receptors, to prevent, inhibit, or ameliorate allograft rejection or arteriosclerosis in organisms that receive an organ transplant.. .
Vegenics Pty Limited

Agent for preventing or ameliorating vascular endothelial malfunction

An agent for preventing or ameliorating vascular endothelial malfunction and arteriosclerosis-related symptoms caused by the progress of vascular endothelial malfunction (e.g., ischemic diseases such as myocardial infarction, angina, and peripheral artery occlusion) or low blood flow-related symptoms (e.g., stiff shoulders, excessive sensitivity to cold, swelling, erectile dysfunction, rough skin and decrease in exercise performance due to skeletal muscle hypoactivity), which has an improved no production enhancing effect is provided. A no production enhancer comprising citrulline or a salt thereof and glutathione or a salt thereof as active ingredients.
Kyowa Hakko Bio Co., Ltd.

Composition for treating hyperlipidemia comprising oxyntomodulin derivative

The present invention relates to a composition for preventing or treating hyperlipidemia, fatty liver disease or arteriosclerosis, comprising an oxyntomodulin derivative as an active ingredient. The oxyntomodulin derivative has a high ability to activate glp-1 receptor and glucagon receptor compared to native oxyntomodulin and has the effects of reducing the blood total cholesterol, low-density cholesterol and triglyceride levels that were increased by high-fat diet, and increasing high-density cholesterol levels and the high-density cholesterol/low-density cholesterol ratio.
Hanmi Pharm. Co., Ltd.

Methods for treatment of cardiovascular disease

This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure..
The Brigham And Women's Hospital, Inc.

1l1rl-1 as a cardiovascular disease marker and therapeutic target

This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure..
The Brigham And Women's Hospital, Inc.

Piperidinylpyrazolopyridine derivative

A compound represented by the general formula (i) or a pharmacologically acceptable salt thereof has an excellent lcat-activating effect and is useful as an active ingredient in a therapeutic or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disturbance, and restenosis caused by angiogenesis), cerebrovascular disease (including stroke and cerebral infarction), peripheral vascular disease (including diabetic vascular complications), dyslipidemia, hypo-hdl-cholesterolemia, or renal disease, particularly, an anti-arteriosclerotic agent, wherein r is an optionally substituted aryl group or an optionally substituted heteroaryl group.. .
Daiichi Sankyo Company, Limited

Lactate salt of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders

Or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thereof; processes for the synthesis or manufacture of the compound of formula (i), or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thereof; and the use of said compound, or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thereof, for the treatment of patients suffering from or subject to diseases, disorders or conditions involving cell survival, proliferation, and migration, including cardiovascular disease (e.g., arteriosclerosis and vascular reobstruction), cancer, (e.g., aml and malignant glioma) glomerulosclerosis, fibrotic disease and inflammation.. .

Quinazoline derivatives as kinase inhibitors

The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases.

Polypeptide having antibacterial activity and angiogenesis-inducing activity and wound-healing drug containing said polypeptide

A novel polypeptide which has an excellent angiogenesis-inducing activity and an excellent antibacterial activity, and a novel angiogenesis-inducing agent which contains the polypeptide as an effective ingredient or a novel agent for treating a wound(s) which contains the polypeptide as an effective ingredient are disclosed. The polypeptide of the present invention is a polypeptide whose amino acid sequence is shown in any one of seq id nos:1 to 6, 8 and 10.

Method for risk stratification in stable coronary artery disease

An in vitro method for the risk stratification of patients with stable arteriosclerosis, especially stable coronary artery disease, is disclosed wherein the concentration of procalcitonin is determined in the circulation of such patients using a highly sensitive pct assay, and wherein within the range of pct concentrations in the typical normal range of healthy individuals cutoff values are defined which distinguish groups of individual patients with stable arteriosclerosis in accordance with personal cardiac risk, and patients are allotted to one of said risk groups on the basis of their individual pct concentrations.. .
B.r.a.h.m.s Gmbh

Methods and compositions for treating arteriosclerotic vascular diseases

The present invention provides methods and compositions for treating arteriosclerotic vascular diseases by cyclohexenone compounds. In some embodiments, the compound in the methods inhibits pdgf-stimulated smooth muscle cell proliferation or migration.
Golden Biotechnology Corporation

Extract formulations of rhodamnia cinerea and uses thereof

The present invention primarily relates to the use of certain extract formulations of rhodamnia cinerea as defined herein as alpha-amylase inhibitors and as actives for the therapeutic (including prophylactic) treatment of a carbohydrate metabolic disorder or of a disease attendant on hyperglycemia, preferably selected from the group consisting of prediabetes, obesity, hyperlipemia, arteriosclerosis, arteriolosclerosis, atherosclerosis, diabetes, postprandial hyperglycemia, and metabolic syndrome. The present invention also relates to corresponding methods.
Biotropics Malaysia Berhad

Pharmaceutical composition for preventing or treating arteriosclerosis

The present invention provides a pharmaceutical composition for preventing or treating arteriosclerosis, comprising: a pharmaceutically effective amount of a protein comprising the amino acid sequence of seq id no: 1; and a pharmaceutically acceptable carrier. The composition of the present invention exhibits no toxicity in the liver or kidney and effectively reduces the formation of atherosclerotic plaques, thereby exhibiting efficacy in treating arteriosclerosis..
Eyegene, Inc.

Monoclonal antibody against el which inhibits enzyme activity of el

Provided is a monoclonal antibody or a fragment thereof that selectively inhibits enzyme activity of el and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.. .
Shionogi & Co., Ltd.

Agent for preventing or ameliorating vascular endothelial malfunction

An agent for preventing or ameliorating vascular endothelial malfunction and arteriosclerosis-related symptoms caused by the progress of vascular endothelial malfunction (e.g., ischemic diseases such as myocardial infarction, angina, and peripheral artery occlusion) or low blood flow-related symptoms (e.g., stiff shoulders, excessive sensitivity to cold, swelling, erectile dysfunction, rough skin and decrease in exercise performance due to skeletal muscle hypoactivity), which has an improved no production enhancing effect is provided. A no production enhancer comprising citrulline or a salt thereof and glutathione or a salt thereof as active ingredients.
Kyowa Hakko Bio Co., Ltd.

Prevention and treatment of cardiovascular diseases using transdermal nitric oxide delivery

The present invention generally relates to compositions and methods for treatment of subjects having or at risk of arteriosclerosis, hypertension, sickle-cell anemia, or other conditions. In some cases, the composition may include nitric oxide.
Transdermal Biotechnology, Inc.

Methods of treating or preventing insulin resistance and associated diseases and conditions

Disclosed are methods of treating an animal for insulin resistance and associated diseases or conditions, activating the transcriptional activity of heat shock factor 1 (hsf1), or inducing the expression of heat shock protein 70 (hsp70) in an animal in need thereof, wherein the methods involve administering an effective amount of one or more compounds of formula (i) or an epimer thereof, wherein ar, and r1-r6 are described herein. Examples of diseases or conditions associated with insulin resistance include diabetes, obesity, inflammation, metabolic syndrome, polycystic ovary disease, arteriosclerosis, non-alcoholic fatty liver disease, reproductive abnormality in a female, and growth abnormality..

Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases

The present methods and compositions are of use for treatment of conditions involving fibrosis, such as peyronie's disease plaque, penile corporal fibrosis, penile veno-occlusive dysfunction, dupuytren's disease nodules, vaginal fibrosis, clitoral fibrosis, female sexual arousal disorder, abnormal wound healing, keloid formation, general fibrosis of the kidney, bladder, prostate, skin, liver, lung, heart, intestines or any other localized or generalized fibrotic condition, vascular fibrosis, arterial intima hyperplasia, atherosclerosis, arteriosclerosis, restenosis, cardiac hypertrophy, hypertension or any condition characterized by excessive fibroblast or smooth muscle cell proliferation or deposition of collagen and extracellular matrix in the blood vessels and/or heart. In certain embodiments, the compositions may comprise a pde-4 inhibitor, a pde-5 inhibitor, a compound that elevates cgmp and/or pkg, a stimulator of guanylyl cyclase and/or pkg, a combination of a compound that elevates cgmp, pkg or no with an antioxidant that decreases ros, or a compound that increases mmp activity..



Arteriosclerosis topics:
  • Arteriosclerosis
  • Vascular Disease
  • Cardiovascular Disease
  • Myocardial Infarction
  • Cardiovascular
  • Infarction
  • Hypertension
  • Hyperlipidemia
  • Fatty Liver
  • Pharmaceutically Acceptable Salt
  • Hypertrophy
  • Cardiac Hypertrophy
  • Recombinant
  • Metabolic Disorder
  • Cerebrovascular


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Arteriosclerosis for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Arteriosclerosis with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.4337

    file did exist - 2493

    2 - 1 - 48